Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Contact: Xiangqing Kong, MD
Not yet recruiting
A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT07753369· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Jian Yong Li, doctor
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
NCT07663253· Shanghai Zhongshan Hospital· Source
Contact: Xiaoyan Qu
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· Phase 3· RemeGen Co., Ltd.· Source
Contact: Yongfeng Yang
Not yet recruiting
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065· First Hospital of China Medical University· Source
Contact: Yonghong Yong
Not yet recruiting
KN5501 Cell Injection for Refractory SLE(CLEAR)
NCT07358988· Phase 1· Ruitherapeutics Co., LTD· Source
Contact: Director of Rheumatology Department
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045· Alpha Biopharma (Jiangsu) Co., Ltd.· Source
Contact: Wen Gao Professor
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822· Phase 2· Peking University· Source
Contact: Hao Wu
Not yet recruiting
Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer
NCT07238959· Shanghai Changzheng Hospital· Source
Contact: Shancheng Ren, MD,PhD
Recruiting
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Yanhong Gu, Doctor
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· Phase 3· Evopoint Biosciences Inc.· Source
Contact: Yingjie zhao
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Yongmei Yin, Doctor
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Chuanlong zhu
Recruiting
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
NCT07455019· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Ge Xiao Lin
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Lei Fan, Doctor
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Kuirong Jiang, Doctor
Not yet recruiting
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Wenfeng Tan, Doctor
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source
Active, not recruiting
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
NCT06702618· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT06754891· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Hongjie Zhang, Doctor
Recruiting
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
NCT06770296· Phase 1· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Yongmei Yin, Ph.D
Active, not recruiting
Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06853769· Early phase 1· The First Affiliated Hospital with Nanjing Medical University· Source
Recruiting
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
NCT06496490· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Renhua Guo, Doctor
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Xiaofeng Chen, Doctor
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Jinhua Luo, M.D.
Recruiting
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
NCT06767813· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Kuirong Jiang, Doctor
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· Phase 3· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Source
Contact: Yongmei Yin
Active, not recruiting
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841· Phase 2· Shanghai Ming Ju Biotechnology Co., Ltd.· Source
Active, not recruiting
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
NCT05799287· Phase 3· RemeGen Co., Ltd.· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Enrolling by invitation
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
NCT04762459· Phase 3· Chinese Academy of Medical Sciences· Source
Recruiting
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
NCT04532606· Phase 4· Peking University First Hospital· Source
Contact: Cun-Ming Liu, MD
Active, not recruiting
Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)
NCT04765605· Hangzhou Endonom Medtech Co., Ltd.· Source
Recruiting
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT04685226· Phase 1/2· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Yongqian Shu, MD
Active, not recruiting
Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer
NCT06926088· The First Affiliated Hospital with Nanjing Medical University· Source